Search results for "Moniti."
showing 10 items of 81 documents
A North American ammonite fauna from the late Middle Turonian of Vaucluse and Gard, southern France: the Romaniceras mexicanum, Prionocyclus hyatti a…
2016
Abstract An unusual, exotic, ammonite fauna including Romaniceras mexicanum Jones, 1938, Prionocyclus hyatti (Stanton, 1894) and Coilopoceras cf. springeri Hyatt, 1903 is recorded from the late Middle Turonian of Vaucluse and Gard, southern France. It is the first record of this ammonite association outside the Gulf Coast region and the Western Interior of the United States of North America. Up to present, these species were considered as endemic to the Western Interior sea-way. The migration of numerous ammonites from North America to western Europe during the late Middle Turonian suggests it is linked to a transgressive event or to a short sea-level high.
Problems in the identity of "Crioceras" barremense Kilian, 1895 (Ancyloceratida, Late Barremian), and their proposed resolution
2010
17 pages; The study of "Crioceras" barremense KILIAN was undertaken as a part of the revision of the Hemihoplitidae. This species was considered "classic" and has been used as the index of an Upper Barremian subzone; this usage raises a number of problems. The type specimen from Tyrol was a fragment described and illustrated by UHLIG as Crioceras sp. ind. aff. roemeri. This specimen could not be retrieved, and a topotype could not be collected. Our study revealed that there is both a biostratigraphic hiatus and important differences between conceptions of this species: (1) that ascribed UHLIG's type specimen (Upper Barremian, Tyrol), (2) KILIAN's concept of the specimen he found and named "…
Pseudoshasticrioceras bersaci nov. sp. (Ammonoidea, Gassendiceratinae), and new ammonite biohorizon for the Upper Barremian of southeastern France
2009
International audience; Research in the Feraudianus Subzone of the Sartousiana Zone of the Barremian stage led to the discovery of a new species of Pseudoshasticrioceras: P. bersaci nov. sp. Its study provides evidence concerning the developments of the latest Gassendiceratinae BERT et alii, 2006, and the relationship between the genus Pseudoshasticrioceras DELANOY, 1998, and Gassendiceras BERT et alii, 2006. In particular, this new species is derived from Pseudoshasticrioceras magnini (DELANOY, 1992) by a minor revision in the processes of ontogenesis (retardation of ornamentation - neoteny). However, the evolution towards Pseudoshasticrioceras autrani DELANOY, 1998, implies a "failure" in…
Les Gregoryceras (Ammonitina) de l'Oxfordien moyen terminal et supérieur téthysien : révision systématique, biostratigraphie et évolution.
2009
43 pages; Les Gregoryceras Spath, 1924 (Ammonitina, Peltoceratina) de la fin de l'Oxfordien moyen (sous-zone à Rotoides) et de la base de l'Oxfordien supérieur (zone à Bifurcatus) sont révisés. Les coupes ayant fourni la plupart des spécimens de ce travail (Espagne et Maghreb) sont décrites et datées sur la base de comparaisons fauniques entre les domaines téthysien et subtéthysien. Le meilleur outil pour ces corrélations est la présence du genre Gregoryceras. La succession des espèces de Gregoryceras est identique pour les deux domaines suscités, ce qui permet de compléter l'échelle biostratigraphique proposée antérieurement et parallèle à la zonation standard. Les espèces reconnues et red…
Physical Activity and Nutrition INfluences In ageing (PANINI): consortium mission statement
2018
First paragraph: Current demographic trends indicate that by the year 2020, almost one in five of the European population will be aged 65 years or over. Although life expectancy is increasing by 2 years per decade, the period of life spent in good health is not keeping pace and most Europeans spend their last decade in poor health. Consequently, there is an urgent need to understand how lifestyle factors can influence age-related changes from gene to society level and how they may be integrated into a net effect of healthy ageing. It is also crucial to develop and validate interventions and health policies to ensure that more of our older adults have a healthy and active later life. This is…
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
2020
PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pem…
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
2019
Approximately one third of patients with non-small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based c…
P164 Cyclophosphamide for the treatment of refractory chronic hypersensitivity pneumonitis
2018
Introduction Intravenous cyclophosphamide at a dose of 600 mg/m2 monthly for 6 months is an established treatment for various immune modulated interstitial lung diseases (ILDs). This practice has been extended to rapidly progressive chronic hypersensitivity pneumonitis (CHP), however, little is known about the therapeutic efficacy in this disease. Methods All patients receiving intravenous cyclophosphamide between 2007 and 2017 at the Royal Brompton Hospital were identified using pharmacy records. Those with a clinical diagnosis of CHP underwent MDT review to confirm the diagnosis. Clinical data, demographics and lung function at time of first treatment and 12 months pre- and post was captu…
Lung microenvironments and disease progression in fibrotic hypersensitivity pneumonitis
2022
Rationale: Fibrotic hypersensitivity pneumonitis (fHP) is an interstitial lung disease caused by sensitization to an inhaled allergen. Objectives: To identify the molecular determinants associated with progression of fibrosis. Methods: Nine fHP explant lungs and six unused donor lungs (as controls) were systematically sampled (4 samples/lung). According to microcomputed tomography measures, fHP cores were clustered into mild, moderate, and severe fibrosis groups. Gene expression profiles were assessed using weighted gene co-expression network analysis, xCell, gene ontology, and structure enrichment analysis. Gene expression of the prevailing molecular traits was also compared with idiopathi…
MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
2020
In the setting of metastatic uveal melanoma (mUM), prognosis is dismal and treatment options are limited. MEK inhibition using selumetinib has led to promising results with improved progression-free survival. While immune checkpoint inhibitors such as programmed cell death-1 (PD-1) blockade therapy (anti-PD-1) has shown discrete efficacy in mUM, combining MEK inhibitors (MEKi) to anti-PD-1 might be an option as such combinations have shown synergistic efficacy in metastatic cutaneous melanoma. We report here and discuss our experience in three patients who received this combination in the absence of suitable alternative treatment. The efficacy was difficult to assess due to early severe tox…